All news

Lilly and Novo bet on amylin for obesity drugs

CNBC · RSS · · AI-summarised by FinFlash

Eli Lilly and Novo Nordisk are developing amylin-based obesity and diabetes treatments, targeting a second biological pathway beyond GLP-1 drugs. Amylin offers an additional lever for weight loss and blood sugar control, as the two companies look to extend their dominance in the fast-growing obesity market. The approach marks a new wave of candidates following the commercial success of GLP-1 therapies.

Read original source

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.